Scholars Central

Conference abstractPublished 28 Aug 2017

Cyclodextrin-based formulations: The present and the future

Authors: Tamas Sohajda

Cyclolab Ltd., Hungary

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cyclodextrins (CDs) are “cone-shaped” cyclic oligosaccharides, with a hydrophobic cavity and hydrophilic outer surface. These nanoscale substances have long been used as functional excipients in different pharmaceuticals due to their ability to encapsulate drugs and alter their disadvantageous features, e.g. increase the aqueous solubility, improve bioavailability, enhance chemical stability or simply to mask their taste. At present more than 40, CD-enabled human pharmaceutical products are on the market. The present of CDs is thus dominantly being used as excipients. The most favored are 2-hydroxypropyl-β- CD (HPBCD) and sulfobutylether-β-CD, applied in dozens of parenteral formulations, while other derivatives are used for oral, topical, nasal or ocular administration. The marvel of CDs lies in their flexibility: you can optimize the excipient for the active ingredient and for the purpose simultaneously. In the present lecture illustrative drug products will be highlighted demonstrating the applicability of derivatized oligosaccharides in the development of drug formulations. Outlook to the future potential related to drug delivery use of CDs will also be provided. CDs tagged with biological recognition-based labeling were prepared in order to deliver specific drugs to the site of action. Also, combinations with the application of colloidal structures (dispersions, liquid crystals and macromolecules) will be discussed. Yet the future of CDs is not limited to being used as excipients. We can harvest from their complex forming ability in vivo as well, in products, containing CDs as APIs. While the initial idea was to use CDs as detoxification agents or to selectively remove chemicals from the system (e.g. Sugammadex – Bridion), this concept has grown into clinical trials and studies using CDs as API alone (HPBCD as an orphan drug against Niemann-Pick C, Focal Segmental Glomerulosclerosis or Alport Syndrome). A number of further therapeutic applications of CDs themselves are expected to come, some potential areas will be reviewed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Tamas Sohajda”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels